AlloMap Heart Molecular Expression Testing
A Genomic Testing Related Image
(Not Necessarily related to the device)Description:
AlloMap Heart Molecular Expression Testing by CareDx Inc.
The AlloMap Heart Molecular Expression Testing by CareDx Inc. represents a paradigm shift in addressing patient care post-heart transplant. This innovative system is exquisitely crafted to monitor the potential risk of acute cellular rejection in patients who have undergone heart transplantation.
Utilizing state-of-the-art genomic technology, AlloMap Heart Molecular Expression Testing employs an intricate algorithm to measure the expression of 20 genes related to immune system activity. By analyzing peripheral blood samples, the technology confers a non-invasive method to generate accurate and relevant risk assessments for acute cellular rejection.
One prominent benefit of AlloMap lies in its invaluable capacity to mitigate the need for invasive endomyocardial biopsies, which were previously the norm for post-transplant surveillance. By granting physicians the ability to identify potential for rejection through a simple blood test, AlloMap heightens patient comfort and convenience while maintaining stringent monitoring standards.
AlloMap Heart Molecular Expression Testing is also proficient in stratifying rejection risk over time. Its regular usage can allow physicians to dynamically tailor immunosuppression therapy, curating individualized patient treatments that offer optimized outcomes. Improve the quality of life for heart transplant recipients with AlloMap's precision characteristic risk scores, enabling a holistic approach to ongoing cardiac care.
CareDx Inc.'s AlloMap Heart Molecular Expression Testing is a manifestation of contemporary genomic medicine's brilliance – facilitating optimal patient care through advanced technology and invaluable innovation in heart transplant management.
Primary Use:
The primary medical use of the device,'AlloMap Heart Molecular Expression Testing' under the 'Cardiac Diagnostic Testing Devices' category, is to aid clinicians in identifying the risk of heart transplant rejection in post-transplant patients. It uses a non-invasive method to provide a molecular insight into the patient's immune system by examining and analyzing the expression levels of a specific set of genes in a blood sample. This gene expression profile, when interpreted along with other clinical indicators, can help doctors determine whether a
How It Works:
AlloMap Heart Molecular Expression Testing
The AlloMap Heart Molecular Expression Testing is a truly revolutionary medical device falling under the umbrella of 'Cardiac Diagnostic Testing Devices.' This non-invasive tool employs groundbreaking techniques in genetic science to provide comprehensive diagnostic assessments of patients with heart transplants, specifically for the risk of organ rejection.
Working Mechanism
The AlloMap test operates by gauging the expression of 20 different genes in a blood sample provided by the patient. This genome profiling approach generates a numerical score between 0 and 40, which is then used to assess the patient's risk of organ rejection.
The selected genes, analyzed in the AlloMap test, are those particularly known to exhibit varied expression levels based on the immune system's activity within the patient. When the body initiates an immune response such as those in organ rejection cases, these genes tend to be noticeably up-regulated or down-regulated. By measuring this expression, AlloMap can provide a credible indication of whether a patient's immune system is actively rejecting a transplanted heart.
Procedure
The procedure for using the AlloMap test is very straightforward. A health professional collects a blood sample from the patient, and this sample is then transported to a lab for further analysis. Using specialized biochemical techniques, the lab technicians isolate the white blood cells that contain genetic information.
The collected RNA is fed through a machine that creates cDNA, a stand-in for the original DNA. This cDNA is applied to a microarray, a specialized chip with spots that bind to the molecules corresponding to the 20 genes in question. Understanding which spots on the microarray are filled allows the expression of the 20 genes to be judged.
Benefits Of The AlloMap Test
The AlloMap test represents a significant advancement in cardiac diagnostic practices, providing a non-invasive alternative to a traditional endomyocardial biopsy. Besides being non-invasive, AlloMap provides actionable data in the critical window of post-transplant monitoring. The valuable insights furnished by this sophisticated tool play an instrumental role in guiding the treatment strategy, adjusting immunosuppression levels and thereby, improving patient outcomes.
Manufacturer:
CareDx Inc.
Status: In Stock
Are you the owner or manufacturer of this device? Need to update anything on this page or get in touch with us? Click here.